ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at Major National Wound Care Meetings

ADDISON, Texas, Sept. 30 /PRNewswire/ -- ULURU Inc. (NYSE Amex: ULU)announced today that the Company will have an extensive presence at the Clinical Symposium on Advances in Skin and Wound Care “CSAWC” which will be held on September 30 October 3, 2010 in Orlando, Florida.

The primary objectives of CSAWC are the education and advancement of clinical practice for wound care professionals. In addition to having a booth presence at the exhibit, ULURU and Altrazeal® will be featured as part of a preconference workshop titled “Two Steps Forward/One Step Back: The Offloading Continuum” being presented by Dr. Greg Bohn, and Dr. James McGuire which will cover diagnosis and treatment of lower extremity diabetic wounds and will present data that includes Altrazeal® in the treatment of offloaded diabetic foot ulcers. ULURU will also present seven scientific posters at the meeting. Further information about CSAWC Fall 2010 is available online at http://symposiumonwoundcare.com.

The posters being presented at CSAWC will include:

• Transforming Powder Dressing combined with Total Contact Cast May Shorten Days to Heal Wagner Grade 2 Neuropathic Diabetic Foot Ulcers.
• Clinical Application of Delayed Time Release PDGF-Carboxymethyl Cellulose Gel in Diabetic Foot Ulcers Using Transforming Powder Dressing as a Delivery Vehicle.
• Powdered Porcine Basement Membrane Extra Cellular Matrix Optimized with Transforming Powder Dressing
• Graft Fixation and Wound Moisture Management with Transforming Powder Dressing

Commenting on ULURU’s participation at the CSAWC, Kerry P. Gray, President and CEO stated, “This is an important forum to present advances in wound treatment using Altrazeal® to a group of wound care professionals. Our presence at this meeting as a sponsor and exhibitor together with the presentation at the preconference workshop will allow us to showcase Altrazeal®, and its clinical benefits, to these clinical professionals who are important current and potential customers. There are now over 50 scientific publications supporting the use of Altrazeal® in both acute and chronic wounds which is a major component of our marketing program as it gives Altrazeal® the necessary clinical and scientific support and credibility.”

ULURU participated at the Symposium of Advanced Wound Care Fall Conference (SAWC) which was held September 23-25, 2010 in Anaheim, California. SAWC organizes the largest wound care conference in the U.S. ULURU staffed a booth to demonstrate the clinical application of Altrazeal® and described the clinical benefits being generated from the use of Altrazeal®. In addition, ULURU presented eight scientific posters on topics ranging from the treatment of venous and diabetic foot ulcers to the incorporation of platelet derived growth factors and anchoring of synthetic skin substitutes with Altrazeal®. Further information on the Fall 2010 SAWC Conference is available at http://fall.sawc.net.

Mr. Gray continued, “Participation at major wound care conferences is an important component in the marketing program of wound care products and is a cost effective way to present Atlrazeal® to many wound care professionals. In addition, these forums are an ideal venue to interact with other wound care companies to discuss strategic relationships.”

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex Aggregate technology and OraDisc delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the clinical benefits of Altrazeal®. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.

SOURCE ULURU Inc.